Mega Consolidation: SeQuent Scientific and Viyash Lifesciences backed by PE Carlyle Group

SeQuent Scientific Limited announced a merger which is expected to create a unique & differentiated platform with leading market position in Animal healthcare segment.

- Anirudha Jain

SeQuent Scientific Limited ("SEQUENT" or "SSL" or "Amalgamated Company"), headquartered in India, operates in Animal Health market with a global footprint. SeQuent has seven manufacturing facilities based in India, Spain, Brazil and Turkey with approvals from various international regulatory bodies. SeQuent currently produces APIs and Animal health formulations in over 100 countries and has more than 1,500 employees. The equity shares of SSL are listed on nationwide bourses. In 2020, The Carlyle Group acquired controlling stake in SSL giving complete exit to erstwhile promoters.

Other company of SSL involved in the proposed transaction is SeQuent Research Limited ("SRL" or Amalgamating Company 2") which is wholly owned subsidiary of SSL.

Viyash Lifesciences (together with various companies as mentioned hereinafter) is an integrated end-to-end pharmaceutical company with a presence across niche formulations, APIs and advanced intermediates. Viyash has an R&D team of 200+ scientists and has 9 USFDA approved plants, signifying strong R&D and manufacturing capabilities.

Viyash serves customers across 150+ countries. List of companies pertaining to Viyash Lifesciences involved in the transaction is as follow:

Viyash Life Sciences Private Limited ("VLSPL" or Transferee Company 1" or Amalgamating Company 1). The company is engaged in the business of development, manufacture and marketing of active pharmaceutical ingredients. The Company is a holding company for all other Viyash group companies.

• Symed Labs Limited ("SLL" or Transferor Company 1") is a wholly owned subsidiary of VLSPL. The company is engaged in manufacturing of bulk drug and intermediates.